|
LARP4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.93930000005993E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.29629999973724E-07 |
| Normal-vs-Stage2 |
7.126200E-02 |
| Normal-vs-Stage3 |
2.33210000000206E-06 |
| Normal-vs-Stage4 |
2.4862999992159E-08 |
| Stage1-vs-Stage2 |
1.195240E-01 |
| Stage1-vs-Stage3 |
3.211600E-01 |
| Stage1-vs-Stage4 |
1.370360E-02 |
| Stage2-vs-Stage3 |
3.528500E-02 |
| Stage2-vs-Stage4 |
3.157400E-03 |
| Stage3-vs-Stage4 |
1.513020E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.34440000021385E-07 |
| Normal-vs-AfricanAmerican |
2.278700E-03 |
| Normal-vs-Asian |
2.636700E-04 |
| Caucasian-vs-AfricanAmerican |
8.520600E-01 |
| Caucasian-vs-Asian |
9.339400E-01 |
| AfricanAmerican-vs-Asian |
9.153800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.99059999994589E-06 |
| Normal-vs-Female |
8.7829999995126E-07 |
| Male-vs-Female |
5.469800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.97450000000354E-05 |
| Normal-vs-Age(41-60Yrs) |
3.11540000019761E-07 |
| Normal-vs-Age(61-80Yrs) |
6.10429999999829E-05 |
| Normal-vs-Age(81-100Yrs) |
2.378600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.478000E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.142600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.578650E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.662400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.306400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.527200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.305800E-01 |
| Classical-VS-Follicular |
3.862400E-01 |
| Classical-VS-Other |
3.691600E-01 |
| Classical-VS-Normal |
4.17790000040164E-07 |
| Tall-VS-Follicular |
8.402000E-02 |
| Tall-VS-Other |
7.439400E-01 |
| Tall-VS-Normal |
3.64790000000337E-05 |
| Follicular-VS-Other |
9.525800E-02 |
| Follicular-VS-Normal |
5.558600E-03 |
| Other-VS-Normal |
8.624400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.23669999977317E-07 |
| Normal-vs-N1 |
5.51730000000195E-05 |
| N0-vs-N1 |
8.666800E-01 |
|
|
